SCHEMBL1743602

SCHEMBL1743602

O=C(NS(=O)(=O)c1ccc(Cl)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1Oc1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1742960 0.91 BCL2 (0.72) —
SCHEMBL1743317 0.91 BCL2 (0.73) —
SCHEMBL2996436 0.89 BCL2 (0.74) —
SCHEMBL1955298 0.88 BCL2 (0.80) —
SCHEMBL1958620 0.88 BCL2 (0.80) —
SCHEMBL1957559 0.88 BCL2 (0.84) —
SCHEMBL1957770 0.88 BCL2 (0.90) —
SCHEMBL1959769 0.88 BCL2 (0.72) —
SCHEMBL1957215 0.88 BCL2 (0.79) —
SCHEMBL1957772 0.88 BCL2 (0.87) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2511264-B1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC (US) 2015-03-11 — — EP claimed
EP-2511264-A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Abbott Laboratories (US) 2012-10-17 — — EP claimed
US-20100184750-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-07-22 — — US claimed
EP-2511264-B1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC (US) 2015-03-11 — — EP disclosed
US-8426422-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2013-04-23 — — US disclosed
EP-2511264-A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Abbott Laboratories (US) 2012-10-17 — — EP disclosed
EP-2387560-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Abbott Laboratories (US) 2011-11-23 — — EP disclosed
US-8042193-B1 Systems and methods for controlling data access by use of a universal anonymous identifier Albright Associates (US) 2011-10-18 — — US disclosed
US-20100184750-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-07-22 — — US disclosed
WO-2010083441-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-07-22 — — WO disclosed
Send feedback